Phase 4
N=110
S. Aureus Screening and Decolonization
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Bottom Line
View on ClinicalTrials.gov: NCT02182115 ↗Enrolled (actual)
110
Serious AEs
12.7%
Results posted
Nov 2017
Primary outcome: Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- antiseptic bundle (Drug); standard of care (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Minnesota
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. |
13; 41 | — |
Summary
Staphylococcus aureus (SA) healthcare-associated infections (HAI) cause significant morbidity and mortality. SA causes 15% of all HAI and 30% of surgical site infections (SSIs). Each year over 40 million Americans undergo operations, 1-10% of whom will acquire SSIs. Such infections double the length of hospitalization and risk of dying, and increase U.S. health care costs by $5-10 billion/year. We need effective interventions to prevent SSIs caused by either methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) strains. Nasal carriers of SA (25-30% of adults) have a 2-14 times greater risk than non-carriers of acquiring an SA SSI. A potential prevention approach is routine pre-operative screening of patients, followed by decolonization of identified SA carriers.
Eligibility Criteria
Inclusion Criteria
- All patient who are 18 years and older, able to give informed consent and willing to complete the study decolonization protocol.
- Surgery must be scheduled 2 weeks in the future to allow completion of the study protocol prior to the scheduled operation.
- Patients will be admitted from home the day of the surgery or have the surgery done on an outpatient basis.
Exclusion Criteria
- Currently on antibiotic therapy, allergy to mupirocin or CHG.
Data sourced from ClinicalTrials.gov (NCT02182115). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.